This story is part of a series on the current progression in Regenerative Medicine. In 1999, I defined regenerative medicine as the collection of interventions that restore tissues and organs damaged ...

To develop the next generation of in vivo T cell therapy, Novartis will leverage Vyriad's active targeting lentiviral vector platform to discover and develop new in vivo CAR-T cell therapy candidates.

Vector-borne diseases cause roughly 700,000 deaths worldwide every year. Vectors can carry different types of pathogens, including viruses and bacteria. Tropical and subtropical regions report large ...